California Stem Cell, Inc. Submits Phase II Clinical Trial Protocol To FDA For Treating Ovarian Cancer
IRVINE, Calif.--(BUSINESS WIRE)--California Stem Cell, Inc. (“CSC”) announced today it has submitted a Phase II protocol to the U.S. Food and Drug Administration for a randomized, double-blind study to evaluate CSC’s patient-specific cancer immunotherapy in women with Stage III or IV ovarian, fallopian tube or primary peritoneal cancer.
Help employers find you! Check out all the jobs and post your resume.